On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made marketing claims that gave a false or misleading impression about their weight loss products.
Under paragraph 74.01(1)(b) of the Competition Act, a person cannot make a claim about a product’s performance, efficacy or length of life unless the claim is based on an adequate and proper test. The Competition Bureau’s investigation concluded that NuvoCare’s weight loss claims were not supported by adequate and proper testing.
As part of the settlement, NuvoCare agreed to pay $100,000 in penalties, change/remove all weight loss claims made about their products, and establish a corporate compliance program to prevent future deceptive marketing issues.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
Related Publications & Articles
-
Federal Court of Appeal dismisses appeal of SPRAVATO “innovative drug” decision
On November 10, 2021, the Minister of Health refused to reassess its decision that Janssen’s esketamine hydrochloride product (SPRAVATO) was not an “innovative drug” and therefore not entitled to data...Read More -
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More